DNMT3A and acute myeloid leukemia: Therefore, despite being one of the most frequently mutated genes in human AML, current clinical risk assessment does not take presence or absence of DNMT3A mutations into account for treatment decisions58 and further investigation to delineate the specific contribution of DNMT3A mutations is warranted.